Company research
KAZIA THERAPEUTICS LTD
CIK 1075880Updated Nov 22, 2026
Historical securities (1)
NVGNF · OTC · equity · closed Oct 13, 2021NVGNF price & chart
This listing closed Oct 13, 2021. Live provider charts are shown only for current listings.
About the company
We are an emerging oncology-focused biotechnology company that has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. Our lead development candidate is paxalisib (formerly known as GDC-0084), a small-molecule, brain-penetrant inhibitor of the PI3K / Akt / mTor pathway, that is being developed as a potential therapy for glioblastoma, the most common and most aggressive form of primary brain tumour in adults, as well advanced breast cancer and as other forms of brain cancer. Our second asset is EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which we licensed from Evotec SE in April 2021.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · AUDSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossAUD | -20,702,000Source | -26,778,000Source | -20,465,180Source | -24,647,815Source |
| Cash flows from financing activities: | ||||
| Dividends paid | —Source | —Source | —Source | — |
| Additional Financial Items | ||||
| AdjustmentsForSharebasedPaymentsAUD | 653,000Source | 533,000Source | 1,159,000Source | 1,675,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsAUD | 310,000Source | -20,000Source | 46,000Source | -1,789,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesAUD | 0Source | 776,000Source | — | — |
| ProceedsFromIssuingSharesAUD | 11,770,000Source | 2,914,000Source | 12,972,000Source | 3,726,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesAUD | 0Source | 371,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseAUD | 8,720,000Source | 13,563,000Source | 8,583,000Source | 4,512,000Source |
| Total RevenueAUD | 42,000Source | — | — | — |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.25Source | 0.25Source | 0.25Source | 0.25Source |
| BasicEarningsLossPerShareAUD/shares | -0.04Source | -0.1Source | -0.11Source | -0.19Source |
| DilutedEarningsLossPerShareAUD/shares | -0.04Source | -0.1Source | -0.11Source | -0.19Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesAUD | 653,194,000Source | 532,597,000Source | 1,159,125Source | 1,674,581Source |
| FinanceIncomeAUD | 72,000Source | 12,000Source | 22,000Source | 2,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillAUD | 6,440,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsAUD | -1,746,000Source | -271,000Source | -271,000Source | -368,000Source |
| NetForeignExchangeLossAUD | — | — | — | 0Source |
| OtherIncomeAUD | 1,787,000Source | 173,000Source | 1,000Source | 25,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansAUD | 1,761,000Source | 2,161,000Source | 2,250,000Source | 1,664,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansAUD | 54,000Source | 88,000Source | 131,000Source | 138,000Source |
| ProfitLossAttributableToOwnersOfParentAUD | -20,702,000Source | -26,778,000Source | -20,465,000Source | -24,648,000Source |
| ProfitLossBeforeTaxAUD | -22,448,000Source | -27,049,000Source | -20,736,000Source | -25,016,000Source |
| ResearchAndDevelopmentExpenseAUD | 7,326,000Source | 17,380,000Source | 15,564,000Source | 20,252,000Source |
| RevenueFromInterestAUD | — | — | 0Source | — |
Offerings
Registration 333-294392
Registration 333-290598
Registration 333-292303
Registration 333-284606
Filing attachments
d883129dex991.htm · 6-K · 2026-11-19
Exhibit 99.1 Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026 SYDNEY, Australia, November 19, 2026 - Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended June 30, 2026 with the U.S. Securities and Exchange Commission (“SEC”). The …
Read attachment ↗d503086dex421.htm · 20-F · 2026-11-17
1 Exhibit 4.21 Certain information identified by [***] has been omitted from this exhibit because it is both not material and is the type that the registrant treats as confidential. Licence Agreement Date 21 March 2024 ───────────────── Parties Kazia Therapeutics Ltd ABN 37 063 259 754 of Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney, New South Wales, Australia 2000 (Kazia) Sovargen Co. Ltd. Business Registration number 475-81-01158 (a company organised und…
Read attachment ↗d503086dex422.htm · 20-F · 2026-11-17
Exhibit 4.22 Certain information identified by [***] has been omitted from this exhibit because it is both not material and is the type that the registrant treats as confidential. LICENSE AGREEMENT This License Agreement (“Agreement”) is entered into and made effective as of 11 June, 2024 (the “Effective Date”), by and between The Council of the Queensland Institute of Medical Research ABN 31 411 813 344 (“Institute”), a not-for-profit institute organized and existing under the laws of the st…
Read attachment ↗d503086dex426.htm · 20-F · 2026-11-17
Confidential Exhibit 4.26 Certain information identified by [***] has been omitted from this exhibit because it is both not material and is the type that the registrant treats as confidential. LICENSE AND COMMERCIALISATION AGREEMENT This LICENSE AND COMMERCIALISATION AGREEMENT (this Agreement”) is made as of 10 April, 2026 (“Effective Date”), by and between KAZIA THERAPEUTICS LIMITED ABN 37 063 259 754 of L24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia, a company organized under the …
Read attachment ↗ea030587301ex99-1.htm · 6-K · 2026-09-22
Exhibit 99.1 Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Australia, September 22, 2026 - Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, …
Read attachment ↗ea030430701ex99-1.htm · 6-K · 2026-09-01
Exhibit 99.1 Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Paxalisib Into a Phase 2 Cl…
Read attachment ↗